RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-1777087
Mesenchymal Stem Cells Applications in Alzheimer's Disease
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202304/lookinside/thumbnails/10-1055-s-0043-1777087_2300073-1.jpg)
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that advances gradually and primarily impacts the hippocampus region of the brain. It is defined by a deterioration in cognitive function as well as an observable loss of memory retention. One of the major characteristics of AD is the impairment of neural generation, resulting in the depletion of neurons and synaptic connections within the nervous system. It is unfortunate to say that, at present, no definitive cure is available for AD, and no medication is effective in halting the progression of neurodegeneration associated with it. Nevertheless, it is crucial to highlight that progress has been achieved in addressing the troubling symptoms of AD. The Food and Drug Administration has granted approval for two categories of medications designed to alleviate these symptoms. The scientific community has been inspired by these advancements to investigate alternative therapeutic options, with an emphasis on stem cell therapy in particular. The main focus of this review will be on the potential for the use of a variety of mesenchymal stem cells as a treatment for AD.
Keywords
Alzheimer's disease (AD) - mesenchymal stem cells - Aβ plaques - microglia - neuroinflammationPublikationsverlauf
Artikel online veröffentlicht:
11. Dezember 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Hu J, Wang X. Alzheimer's disease: from pathogenesis to mesenchymal stem cell therapy - bridging the missing link. Front Cell Neurosci 2022; 15: 811852
- 2 Duncan T, Valenzuela M. Alzheimer's disease, dementia, and stem cell therapy. Stem Cell Res Ther 2017; 8 (01) 111
- 3 Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol 2018; 25 (01) 59-70
- 4 Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease. Curr Neuropharmacol 2020; 18 (11) 1106-1125
- 5 Breijyeh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules 2020; 25 (24) 5789
- 6 Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Mol Med Rep 2019; 20 (02) 1479-1487
- 7 Eldufani J, Blaise G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications. Alzheimers Dement (N Y) 2019; 5: 175-183
- 8 Liu J, Chang L, Song Y, Li H, Wu Y. The role of NMDA receptors in Alzheimer's disease. Front Neurosci 2019; 13: 43
- 9 Folch J, Busquets O, Ettcheto M. et al. Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis 2018; 62 (03) 1223-1240
- 10 Yao P, Zhou L, Zhu L, Zhou B, Yu Q. Mesenchymal stem cells: a potential therapeutic strategy for neurodegenerative diseases. Eur Neurol 2020; 83 (03) 235-241
- 11 Liu C. The role of mesenchymal stem cells in regulating astrocytes-related synapse dysfunction in early Alzheimer's disease. Front Neurosci 2022; 16: 927256
- 12 Regmi S, Liu DD, Shen M. et al. Mesenchymal stromal cells for the treatment of Alzheimer's disease: strategies and limitations. Front Mol Neurosci 2022; 15: 1011225
- 13 Uddin MS, Stachowiak A, Mamun AA. et al. Autophagy and Alzheimer's disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci 2018; 10: 04
- 14 Kuang H, Tan CY, Tian HZ. et al. Exploring the bi-directional relationship between autophagy and Alzheimer's disease. CNS Neurosci Ther 2020; 26 (02) 155-166
- 15 Qin C, Bai L, Li Y, Wang K. The functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer's disease: crosstalk between autophagy and apoptosis. Stem Cell Res Ther 2022; 13 (01) 90
- 16 Li X, Song J, Dong R. Cubeben induces autophagy via PI3K-AKT-mTOR pathway to protect primary neurons against amyloid beta in Alzheimer's disease. Cytotechnology 2019; 71 (03) 679-686
- 17 Kerr JS, Adriaanse BA, Greig NH. et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci 2017; 40 (03) 151-166
- 18 Qin C, Li Y, Wang K. Functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer's disease: inhibition of neuroinflammation. J Inflamm Res 2021; 14: 4761-4775
- 19 Singh P, Fukuda S, Liu L, Chitteti BR, Pelus LM. Survivin is required for mouse and human bone marrow mesenchymal stromal cell function. Stem Cells 2018; 36 (01) 123-129
- 20 Deng W, Fan C, Fang Y. et al. Role of XIAP gene overexpressed bone marrow mesenchymal stem cells in the treatment of cerebral injury in rats with cerebral palsy. Cancer Cell Int 2019; 19: 273
- 21 Sánchez-Castillo AI, Sepúlveda MR, Marín-Teva JL. et al. Switching roles: beneficial effects of adipose tissue-derived mesenchymal stem cells on microglia and their implication in neurodegenerative diseases. Biomolecules 2022; 12 (02) 219
- 22 Hernández AE, García E. Mesenchymal stem cell therapy for Alzheimer's disease. Stem Cells Int 2021; 2021: 7834421
- 23 Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 2023; 8 (01) 359
- 24 Neubrand VE, Forte-Lago I, Caro M, Delgado M. The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia. [published correction appears in J Neuroinflammation. 2019 Feb 12;16(1):31]. J Neuroinflammation 2018; 15 (01) 343
- 25 Park SE, Kim HS, Kwon SJ. et al. Exposure of mesenchymal stem cells to an Alzheimer's disease environment enhances therapeutic effects. Stem Cells Int 2021; 2021: 6660186
- 26 Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res 2019; 7: 8
- 27 Guo M, Yin Z, Chen F, Lei P. Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer's disease. Alzheimers Res Ther 2020; 12 (01) 109
- 28 Cone AS, Yuan X, Sun L. et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model. Theranostics 2021; 11 (17) 8129-8142
- 29 Reza-Zaldivar EE, Hernández-Sapiéns MA, Gutiérrez-Mercado YK. et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer's disease. Neural Regen Res 2019; 14 (09) 1626-1634
- 30 Xie M, Xiong W, She Z. et al. Immunoregulatory effects of stem cell-derived extracellular vesicles on immune cells. Front Immunol 2020; 11: 13
- 31 Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol 2021; 12: 749192
- 32 Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics 2021; 11 (07) 3183-3195